Breaking News Instant updates and real-time market news.

ABT

Abbott

$81.82

-0.84 (-1.02%)

16:08
09/29/19
09/29
16:08
09/29/19
16:08

Abbott announces outcomes data for device to repair leaky Tricuspid heart valves

Abbott announced new data that suggest Abbott's investigational TriClip device may offer physicians an effective minimally invasive repair option for patients suffering from a leaky tricuspid valve, a condition also known as tricuspid regurgitation. For patients suffering from moderate to severe TR, the new data found treatment with TriClip was safe and associated with strong clinical improvement at six-months, including a reduction in TR and improvement in quality of life. The results build upon the initial 30 day data from the TRILUMINATE Feasibility Study, which suggested the promise of TriClip in treating people suffering from this difficult-to-manage structural heart disease. After six months, the TRILUMINATE Feasibility Study showed patients who received Abbott's TriClip device saw a number of benefits, including: Reduction of tricuspid regurgitation - Within the study, 87% of patients had a reduction in their TR at 6 months, with 57% of patients implanted having a TR classification of moderate or better vs. only 6% of patients with the same classification at the time of enrollment; Symptom improvement - Patients receiving TriClip had reduction in their symptoms, with 87% of patients implanted with TriClip being classified as NYHA functional class I/II at six months versus only 25% of patients receiving the same classification at the time of enrollment; Quality of life improvements - Patients receiving TriClip showed improved KCCQ scores and a reduction in symptoms that are associated with a reduced burden of their clinical condition and improved physical output. The TRILUMINATE Feasibility study was a prospective, single-arm, multi-center study, which investigated the performance of Abbott's proven clip-based repair technology using the tricuspid valve repair system, TriClip, in 21 sites across the U.S. and Europe.

  • 16

    Oct

ABT Abbott
$81.82

-0.84 (-1.02%)

07/18/19
BMOC
07/18/19
NO CHANGE
Target $94
BMOC
Outperform
Abbott price target raised to $94 from $87 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Abbott to $94 and kept her Outperform rating after its Q2 earnings beat and a raise in FY19 guidance, saying the company is among a "handful" of medtech names that deliver above-market revenue and double-digit earnings growth along with operating leverage. The analyst notes that following its AbbVie spinoff and acquisition of St. Jude Medical and Alere, Abbott's growth drivers of Alinity, Libre and MitraClip are "humming along" - a trend she expects to continue.
07/18/19
COWN
07/18/19
NO CHANGE
Target $95
COWN
Outperform
Abbott price target raised to $95 from $86 at Cowen
Cowen analyst Joshua Jennings raised his price target on Abbott to $95 from $86 following Q2 earnings. The analyst said the quarter's highlight was the organic sales growth of 7.5% which was above its target of 7.0%, reflecting continued strength for Libre, MitraClip, and Alinity. He noted management raised it guidance for organic sales growth and earnings and he believes the company can continue to post above consensus results in the second half of the year. Jennings reiterated his Outperform rating on Abbott shares.
07/18/19
JEFF
07/18/19
NO CHANGE
Target $98
JEFF
Buy
Abbott price target raised to $98 from $80 at Jefferies
Jefferies analyst Raj Denhoy raised his price target for Abbott Laboratories to $98 from $80 saying the company's growth story is "still going strong" following its Q2 results. The quarter is more proof that the pharma exit and medtech "double-down" was right move, Denhoy tells investors in a research note. Despite Abbott's "strong" current momentum, each product cycle is still in early innings, adds the analyst. He keeps a Buy rating on the shares.
09/23/19
PIPR
09/23/19
NO CHANGE
Target $182
PIPR
Overweight
DexCom remains a 'must own' stock for investors, says Piper Jaffray
After hosting meetings with management, Piper Jaffray analyst JP McKim believes DexCom (DXCM) remains "a must own for investors." First off, the analyst does not believe the company was "walking down" numbers at a recent investor conference. Continuous glucose monitoring demand remains "robust" and importantly, G7 is only 12-15 months away, McKim tells investors in a research note. The analyst also left the meetings "with a lot more bullishness" on the hospital market as well as the non-intensive Type 2 market, where he believes DexCom's sensor technology will have an impact. McKim does expect share volatility around the near-term approval of Abbott's (ABT) Libre 2.0 with integrated continuous glucose monitoring, but he believes the impact DexCom "will be short lived in nature." McKim keeps an Overweight rating on the shares with a $182 price target. The stock closed Friday down 59c to $154.40.

TODAY'S FREE FLY STORIES

CTLT

Catalent

$48.83

-0.39 (-0.79%)

07:22
10/17/19
10/17
07:22
10/17/19
07:22
Initiation
Catalent initiated  »

Catalent resumed with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 05

    Nov

CDEV

Centennial Resource Development

$3.42

0.09 (2.70%)

07:22
10/17/19
10/17
07:22
10/17/19
07:22
Hot Stocks
Centennial Resource Development appoints Steven Shapiro to board of directors »

Centennial Resource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

CAKE

Cheesecake Factory

$38.41

0.06 (0.16%)

07:21
10/17/19
10/17
07:21
10/17/19
07:21
Downgrade
Cheesecake Factory rating change  »

Cheesecake Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 04

    Nov

  • 12

    Nov

NFLX

Netflix

$286.83

2.59 (0.91%)

07:20
10/17/19
10/17
07:20
10/17/19
07:20
Recommendations
Netflix analyst commentary  »

Netflix guidance adds…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

AKG

Asanko Gold

$0.90

-0.0083 (-0.91%)

, GFI

Gold Fields

$5.52

0.15 (2.79%)

07:19
10/17/19
10/17
07:19
10/17/19
07:19
Hot Stocks
Asanko Gold reports Q3 AGM gold production of 62,440 ounces »

Asanko Gold (AKG)…

AKG

Asanko Gold

$0.90

-0.0083 (-0.91%)

GFI

Gold Fields

$5.52

0.15 (2.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$286.83

2.59 (0.91%)

07:17
10/17/19
10/17
07:17
10/17/19
07:17
Recommendations
Netflix analyst commentary  »

Stifel keeps Buy rating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

OLN

Olin

$18.25

-0.015 (-0.08%)

, WLK

Westlake Chemical

$62.28

-0.24 (-0.38%)

07:17
10/17/19
10/17
07:17
10/17/19
07:17
Downgrade
Olin, Westlake Chemical rating change  »

JPMorgan downgrades Olin…

OLN

Olin

$18.25

-0.015 (-0.08%)

WLK

Westlake Chemical

$62.28

-0.24 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 05

    Nov

NURO

NeuroMetrix

$0.32

-0.0249 (-7.21%)

07:15
10/17/19
10/17
07:15
10/17/19
07:15
Earnings
NeuroMetrix reports Q3 revenue $2.1M, one estimate $3.93M »

"A new commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 12

    Nov

NFLX

Netflix

$286.83

2.59 (0.91%)

07:13
10/17/19
10/17
07:13
10/17/19
07:13
Recommendations
Netflix analyst commentary  »

Netflix's Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

CMA

Comerica

$65.50

-1.505 (-2.25%)

07:13
10/17/19
10/17
07:13
10/17/19
07:13
Downgrade
Comerica rating change  »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCBI

Texas Capital

$54.33

-0.15 (-0.28%)

07:12
10/17/19
10/17
07:12
10/17/19
07:12
Recommendations
Texas Capital analyst commentary  »

Texas Capital price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$79.12

0.8 (1.02%)

07:11
10/17/19
10/17
07:11
10/17/19
07:11
Hot Stocks
Philip Morris backs FY19 currency-neutral net revenue growth of at least 6% »

Lowers FY19 capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

GOLD

Barrick Gold

$16.95

0.3 (1.80%)

07:11
10/17/19
10/17
07:11
10/17/19
07:11
Hot Stocks
Barrick Gold sees FY production towards upper end of 5.1M-5.6M ounce guidance »

Barrick Gold Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

PFE

Pfizer

$36.34

-0.17 (-0.47%)

07:10
10/17/19
10/17
07:10
10/17/19
07:10
Initiation
Pfizer initiated  »

Pfizer reinstated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 06

    Nov

MAIN

Main Street

$42.08

0.155 (0.37%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Earnings
Main Street declares semi-annual supplemental cash dividend of 24c in December »

Main Street declared its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

POOL

Pool Corp.

$200.56

-4.63 (-2.26%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Earnings
Pool Corp. raises FY19 EPS view $6.20-$6.40 from $6.09-$6.34 

Consensus $6.22.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 13

    Nov

PM

Philip Morris

$79.12

0.8 (1.02%)

07:08
10/17/19
10/17
07:08
10/17/19
07:08
Hot Stocks
Philip Morris revises FY19 shipment volume assumption to "down 1% - down 1.5" »

Prior guidance was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

AZN

AstraZeneca

$43.80

-0.41 (-0.93%)

07:07
10/17/19
10/17
07:07
10/17/19
07:07
Hot Stocks
AstraZeneca says trastuzumab deruxtecan granted FDA Priority Review »

AstraZeneca and Daiichi…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 06

    Nov

POOL

Pool Corp.

$200.56

-4.63 (-2.26%)

07:07
10/17/19
10/17
07:07
10/17/19
07:07
Earnings
Pool Corp. reports Q3 EPS ex-items $1.84, consensus $1.78 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 13

    Nov

TXMD

TherapeuticsMD

$3.70

-0.22 (-5.61%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Initiation
TherapeuticsMD initiated  »

TherapeuticsMD initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$79.12

0.8 (1.02%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Earnings
Philip Morris lowers FY19 EPS view to 'at least $4.73' from 'at least $4.94' »

Consensus $5.21. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

NFLX

Netflix

$286.83

2.59 (0.91%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Recommendations
Netflix analyst commentary  »

KeyBanc lowers estimates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

NBRV

Nabriva Therapeutics

$2.01

0.08 (4.15%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Conference/Events
Nabriva Therapeutics management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

BBIO

BridgeBio

$17.92

-0.6 (-3.24%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Hot Stocks
BridgeBio reports preclinical data on infigratinib in treating achondroplasia »

BridgeBio Pharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCBJY

UCB

$0.00

(0.00%)

07:05
10/17/19
10/17
07:05
10/17/19
07:05
Hot Stocks
UCB says bimekizumab Phase 3 psoriasis study meets all endpoints »

UCB announced positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.